ArticleSurgical endoscopy2026
RedoPOEM: efficacy and safety after failure of a first POEM for esophageal motility disorders.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06044155 (Efficacy and Safety After Failure of a First POEM), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety After Failure of a First POEM
Who cites it
1 citing paper in PubMed.
- Laparoscopic Heller-Dor as salvage therapy after failed POEM: a prospective comparative study.Surgical endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPer-oral endoscopic myotomy (POEM) achieves an 80-90% success rate for the treatment of esophageal motility disorders, but approximately 10% of patients experience persistent symptoms. This study evaluated the results of a repeat POEM procedure, or redoPOEM, as a second-line therapy.
methodsWe conducted a retrospective multicenter study involving 15 French tertiary centers, including all patients undergoing redoPOEM between April 2015 and September 2023. Short and long-term success rates were defined as an Eckardt score < 4 at 3 months, and at the last follow-up visit with no need for additional treatment, respectively. Adverse events were graded using the AGREE classification.
resultsEighty-seven patients (mean age 56.5 years, 57% male) were included; 89.7% had achalasia and 10.3% had non-achalasia motility disorders. The median pre-redoPOEM Eckardt score was 6. The average follow-up duration was 22 months. At 3 months, 78.2% achieved clinical success (median Eckardt score: 1). Long-term success was obtained in 57.1% at 1 year follow-up. Additional treatments were required in 28%. Univariate and multivariate analyses identified a high pre-redoPOEM Eckardt score and prior treatments before POEM as predictors of failure. Adverse events (grade II or higher) occurred in 11.4%, including pneumonia and mucosal breaches, but no deaths were reported.
conclusionRedoPOEM is effective and safe for managing primary failure or symptomatic recurrence after a first POEM. A high pre-redoPOEM Eckardt score and previous treatments are predictive of primary failure. CLINICAL TRIALS NUMBER: NCT06044155.
Indexed as
Identifiers
41575544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.